AbbVie (ABBV) Tops Q3 EPS by 10c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
AbbVie (ABBV) Announces FDA Approval of VUITY 1.25%, the First and Only Eye Drop to Treat Presbyopia
October 29, 2021 5:33 PM EDTAllergan, an AbbVie (NYSE: ABBV) company, today announced the U.S. Food and Drug Administration (FDA) approval of VUITY (pilocarpine HCl ophthalmic solution) 1.25% for the treatment of presbyopia, commonly known as age-related blurry near vision, in adults. VUITY is the first and only FDA-approved eye drop to treat this common and progressive eye condition that affects 128 million Americans, nearly half of the U.S. adult population.
"Most adults cope with presbyopia, or difficulty with near vision, as we age. Beginning around the age of 40, many find themselves using reading glasses, holding text... More
AddVie (ABBV) Continues to Deliver, Despite Concerns - Analyst
October 29, 2021 9:04 AM EDTEarlier today, AbbVie (NYSE: ABBV) reported its Q3 results: EPS of $3.33, $0.10 better than the analyst estimate of $3.23; Revenue of $14.34 billion versus the consensus estimate of $14.35 billion.
The company also raised its adjusted diluted EPS for the full-year 2021 from $12.52 to $12.62 to $12.63 to $12.67.
Commenting on the earnings readout, Mizuho analyst Vamil Divan is encouraged by the company's continued strong performance and outlook, even as he awaits greater clarity... More
AbbVie's (ABBV) Cariprazine Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder
October 29, 2021 7:51 AM EDTAbbVie (NYSE: ABBV) today announced top-line results from two Phase 3 clinical trials, Study 3111-301-001 and Study 3111-302-001, evaluating the efficacy and safety of cariprazine (VRAYLAR®) as an adjunctive treatment for patients with major depressive disorder (MDD). In Study 3111-301-001, cariprazine showed a statistically significant change from baseline to week six in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score compared with placebo. Patients treated with cariprazine at 1.5 mg/day achieved improved MADRS total score at week six compared to placebo (p-value=0.0050). Patients treated with cariprazine at 3.0 mg/day demonstrated... More
